The Addition of Darolutamide to ADT Reduces Risk of Metastasis in Nonmetastatic CRPC
Karim Fizazi, MD, PhD, discusses the potential role for darolutamide in combination with androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer.
Karim Fizazi, MD, PhD, head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France, discusses the potential role for darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
According to data from the phase III ARAMIS trial, darolutamide, when combined with ADT, resulted in a median metastasis-free survival of 40.4 months compared with 18.4 months with ADT alone. There was also a trend toward improvement in overall survival (OS), but the median OS data were still not mature. The 3-year OS rate is 83% with the combination versus 73% with ADT alone, Fizazi says.
The addition of darolutamide led to a 59% reduction in the risk of metastasis or death. The drug also had a good safety profile with minimal adverse events compared to placebo. Quality of life, assessed by the FACT-P and EORTC questionnaire, was maintained with the combination versus ADT alone.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
